Abaloparatide
Also known as Tymlos, BA058
Abaloparatide (Tymlos) is an approved daily injection that actively builds new bone, used to treat osteoporosis and cut fracture risk in people with fragile bones.
Synthetic analog of PTH-related protein (PTHrP 1-34) for postmenopausal osteoporosis at high fracture risk. Once-daily subcutaneous injection.
Mechanism of action
Selective agonism of the PTH1 receptor's RG conformation drives bone formation with comparatively less resorption than PTH.
Approved drug (Tymlos). Terminal half-life ~1–1.7 h. Lifetime use of bone-anabolic agents is limited — follow prescribing guidance.
Track Abaloparatide for free
Log your doses and PeptideBuddy models Abaloparatide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free